Theodora Mantzourani
Private GP, UK
Title: “Tribitor® reduces caloric impact of sugar, glycaemic index of food & glucose and insulin spikes after high carbohydrate meals†– the latest clinical studies
Biography
Biography: Theodora Mantzourani
Abstract
All dietary carbohydrates are converted into glucose after digestion. Carbohydrate digestion and absorption is a multistage process involving enzymes and transporter proteins. High Glycemic index (GI) carbohydrates are broken down fast during digestion and release glucose rapidly into the bloodstream; low GI carbohydrates are broken down more slowly and release glucose more gradually. High intake of carbohydrates especially those with high GI together with environmental factors contributes to obesity, metabolic syndrome and diabetes.
A new product (Tribitor®) was developed during animal and human studies. During OGTT animal studies performed in rats, different plant extracts were tested for their hypoglycemic effects and after performed comparisons, the plant extracts with the highest hypoglycemic capacities were included into combinations tested for best synergistic hypoglycemic effect. The combination of three extracts with the greatest ability to lower postprandial glycaemia was chosen for further testing in humans. Two randomized, double- blind, placebo controlled studies were performed to GCP standards to verify the hypoglycemic effects of Tribitor®. The effects of this preparation on blood glycaemia were monitored after consumption of different meals. Statistically significant reductions of glucose and insulin peak levels were observed, particularly during the first phase of the test. Reactive hypoglycemia events were observed significantly less frequently when Tribitor® was given before meals. It was also found in a follow-up study, that Tribitor® had the ability to lower the Glycemic Index of white bread.
In summary, Tribitor® is an innovative, patent-pending carbohydrate-blocking technology containing an optimum complex of three standardized plant extracts. Its clinically proven three-phase action reduces glucose and insulin peaks which, in turn, helps reduce the risk of obesity, insulin resistance and reactive hypoglycemia.